Detalhe da pesquisa
1.
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Oncologist
; 28(11): 978-985, 2023 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589215
2.
Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival.
Eur Radiol
; 33(10): 7284-7293, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37099174
3.
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers.
Res Sq
; 2024 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38313284
4.
Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology.
Ther Adv Med Oncol
; 16: 17588359241231260, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38455708
5.
Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy.
JAMA Oncol
; 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38780929
6.
Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors.
JCO Precis Oncol
; 8: e2300439, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38330262
7.
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer.
JCO Precis Oncol
; 8: e2300371, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38330261
8.
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.
J Clin Oncol
; 42(11): 1311-1321, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38207230
9.
Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors.
Cancer Discov
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38564707
10.
Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib.
JCO Precis Oncol
; 7: e2300295, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37972337
11.
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.
Cancer Cell
; 41(10): 1731-1748.e8, 2023 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37774698
12.
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC.
Nat Commun
; 14(1): 4238, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37454214
13.
Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
JAMA Oncol
; 9(1): 51-60, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36394839
14.
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
J Immunother Cancer
; 11(7)2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37487667
15.
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer.
J Immunother Cancer
; 11(11)2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37914383
16.
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
J Thorac Oncol
; 18(6): 731-743, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36775193
17.
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.
J Thorac Oncol
; 18(11): 1524-1537, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37247843
18.
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.
Clin Cancer Res
; 29(13): 2540-2550, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37097610
19.
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res
; 29(21): 4408-4418, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37432985
20.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Cancer Discov
; 13(7): 1556-1571, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068173